![Andrew Partridge](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Andrew Partridge
Corporate Officer/Principal en TURG POIN .
Cargos activos de Andrew Partridge
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
TURG POIN | Corporate Officer/Principal | 13/07/2020 | - |
Historial de carrera de Andrew Partridge
Antiguos cargos conocidos de Andrew Partridge.
Empresas | Cargo | Inicio | Fin |
---|---|---|---|
CENTREXION THERAPEUTICS CORPORATION | Corporate Officer/Principal | 24/09/2018 | 02/07/2020 |
VERTEX PHARMACEUTICALS INCORPORATED | Corporate Officer/Principal | 01/01/2013 | 01/11/2018 |
AMGEN INC. | Ventas & Marketing | 01/01/2003 | 01/01/2013 |
Estadísticas
Internacional
Estados Unidos | 5 |
Operativa
Corporate Officer/Principal | 3 |
Sales & Marketing | 1 |
Sectorial
Health Technology | 5 |
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Empresas relacionadas
Empresas cotizadas | 2 |
---|---|
VERTEX PHARMACEUTICALS INCORPORATED | Health Technology |
AMGEN INC. | Health Technology |
Empresas privadas | 2 |
---|---|
Centrexion Therapeutics Corp.
![]() Centrexion Therapeutics Corp. Pharmaceuticals: MajorHealth Technology Centrexion Therapeutics Corp. is a clinical-stage biopharmaceutical company, which engages in identifying, developing, and commercializing novel, non-opioid, and non-addictive therapies to address the large unmet medical need for the treatment of chronic pain. Its product pipeline includes CNTX-4975, CNTX-0290, CNTX-6970, CNTX-2022, CNTX-6016, and intrathecal platform. The company was founded by Sol J. Barer and Jeffrey B. Kindler in February 2013 and is headquartered in Boston, MA. | Health Technology |
Turning Point Therapeutics, Inc.
![]() Turning Point Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Turning Point Therapeutics, Inc. is a clinical-stage oncology biopharmaceutical company, which engages in designing and developing next-generation therapies that target genetic drivers of cancer to improve the lives of patients. Its product pipeline include Repotrectinib, TPX-0022, TPX-0046, and TPS-O131, a next-gen ALK inhibitor. The company was founded by Jingrong Jean Cui and Y. Peter Li in October 2013 and is headquartered in San Diego, CA. | Health Technology |
- Bolsa de valores
- Insiders
- Andrew Partridge
- Experiencia